Attention-Deficit/Hyperactivity Disorder (ADHD) is a heterogeneous neurodevelopmental condition with substantial interindividual variability in symptom expression, cognitive control, and neurophysiological signatures. Despite decades of evidence implicating EEG-derived markers—such as altered theta, alpha, and beta power and event-related potentials (ERPs) including N2 and P3 components—routine clinical translation has remained limited. Variability in methods, populations, and data interpretation has hindered standardization and reproducibility. Converging meta-analytic findings, however, indicate that EEG-based neurofeedback offers additive short-term benefits when combined with medication, particularly for parent-rated global and inattention symptoms. Yet these effects tend to attenuate at six months, highlighting the need for objective, standardized monitoring frameworks. The BrainView platform represents a pragmatic, FDA-cleared ecosystem for embedding quantitative EEG (qEEG) and ERP measures into ADHD assessment, treatment monitoring, and research. Here, we outline how BrainView enables neurophysiology-informed phenotyping, individualized treatment optimization, and objective tracking of neural change. By integrating standardized spectral and ERP metrics with clinical outcomes, BrainView bridges the translational gap between laboratory EEG biomarkers and actionable clinical decision- making, supporting reproducibility, harmonization, and meta-science in ADHD neurophysiology.